These results suggested that IL11 mutein competitively inhibit IL11, and IL11 mutein-treated tumor was suppressed, in which CXCL9 and MHC-I molecules were upregulated and CD8+ T infiltration was increased. The gene discussed is CD8A; the disease is neoplasm.